Stay updated on Evobrutinib Study in RMS Patients Clinical Trial

Sign up to get notified when there's something new on the Evobrutinib Study in RMS Patients Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Evobrutinib Study in RMS Patients Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:55:09.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a change in the active comparator in a phase 3 clinical trial for participants with Relapsing Multiple Sclerosis (RMS). This change led to the early termination of the trial involving the study of Evobrutinib compared with Interferon Beta 1a (Avonex®) in participants with RMS.
    Difference
    0.1%
    Check dated 2024-06-06T14:33:50.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a more detailed description, now labeled 'Participation Criteria,' explaining that researchers seek individuals who meet specific eligibility criteria, such as general health condition or prior treatments. This change provides a clearer understanding of the criteria used to select participants for clinical research studies.
    Difference
    25%
    Check dated 2024-05-22T21:23:03.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:44:11.000Z thumbnail image

Stay in the know with updates to Evobrutinib Study in RMS Patients Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Evobrutinib Study in RMS Patients Clinical Trial page.